RWF_14-116

A Pilot Study of DPV-001 DRibble Vaccine with Imiquimod in Advanced Prostate Cancer

This is a phase II trial of allogeneic DRibble vaccine, DPV-001, CTX and imiquimod to treat castrate resistant prostate cancer that has failed prior systemic therapy.

Key Eligibility:

* Subjects have measurable or evaluable metastatic castrate resistant adenocarcinoma of the prostate with progression after chemotherapy, combined androgen blockade and/or peripheral androgen or androgen receptor suppression. Either histologic or serum marker diagnosis is acceptable.
Pilot/Feasibility
NCT02234921
Oncology
Genitourinary
Brendan Curti, M.D.
Earle A Chiles Research Institute (EACRI)
Scot Lary
  • Oncology and Hematology Care Eastside